PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. The company's products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. PAVmed was founded on June 26, 2014 and is headquartered in New York, NY.
Clinical Trials
2
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Completed
2
100.0%
No approval data available
- Veris Health and The Ohio State University Comprehensive Cancer Center have launched the commercial phase of their strategic partnership to deploy the Veris Cancer Care Platform across the cancer center. - The digital platform provides remote physiological monitoring, symptom reporting, and telehealth capabilities to enhance personalized cancer care and reduce unplanned hospitalizations. - Cancer patients receive a VerisBox of connected healthcare devices that transmit physiologic data to clinicians via cellular connections, with a complementary smartphone app for symptom reporting. - The partnership expands from pilot phase to full engagement across The James, including launching a clinical registry for patients enrolled on the platform.
- Lucid Diagnostics has partnered with LEAA Health to offer its EsoGuard Esophageal DNA Test to concierge medicine patients on a cash-pay basis, targeting the growing $10.9 billion concierge medicine market projected by 2032. - Highmark Blue Cross Blue Shield has issued the first positive commercial insurance coverage policy for Lucid's EsoGuard test in New York state, marking a significant milestone that could influence other insurers to follow suit. - The EsoGuard test provides non-invasive screening for esophageal precancer and cancer in patients with gastroesophageal reflux disease (GERD), potentially enabling earlier intervention and improved patient outcomes.
- A new study demonstrates the clinical utility of Lucid Diagnostics' EsoGuard test for detecting Barrett's Esophagus. - The study showed a high patient compliance rate of 85% with referrals to confirmatory upper endoscopy after positive EsoGuard results. - EsoGuard effectively triages patients at increased risk for esophageal precancer, reducing the need for invasive procedures. - The test exhibits near-perfect provider decision impact, with consistent referral patterns based on test results.
